Suppr超能文献

5-HT2C/5-HT2B受体拮抗剂SB 200646A在两种焦虑冲突模型中的作用。

Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety.

作者信息

Kennett G A, Bailey F, Piper D C, Blackburn T P

机构信息

SmithKline Beecham, Harlow, Essex, UK.

出版信息

Psychopharmacology (Berl). 1995 Mar;118(2):178-82. doi: 10.1007/BF02245837.

Abstract

SB 200646A is the first selective 5-HT2C/5-HT2B receptor antagonist and has previously been observed to have anxiolytic-like properties in the rat social interaction test. In the present study the effects of the compound in two conflict models of anxiety, the rat Geller-Seifter and marmoset conflict test, were examined. In the rat Geller-Seifter test, suppressed responding was increased by all doses of SB 200646A between 5 and 40 mg/kg PO when given 1 h pretest. Unsuppressed responding was slightly increased only at 10 mg/kg PO. Suppressed responding was also increased by the benzodiazepine anxiolytic, chlordiazepoxide, at 1, 2.5 and 5 mg/kg PO 1 h pretest. Unsuppressed responding was modestly increased by chlordiazepoxide only at 5 mg/kg PO. In the marmoset conflict test marmosets were trained to lever press for a palatable food reward. Lever pressing was subsequently suppressed by air puffs. In this procedure suppressed responding was increased by both the benzodiazepine anxiolytic diazepam at 2 and 5 mg/kg PO and SB 200646A after 10 and 20 mg/kg PO. Both treatments caused small increases in unsuppressed responding at 2 and 20 mg/kg PO respectively. Taken together with the previous effects of SB 200646A in the rat social interaction test, this is compelling evidence that 5-HT2C/2B receptor antagonists may possess anxiolytic properties.

摘要

SB 200646A是首个选择性5-HT2C/5-HT2B受体拮抗剂,此前在大鼠社交互动试验中已观察到它具有类抗焦虑特性。在本研究中,检测了该化合物在两种焦虑冲突模型(大鼠盖勒-西弗特试验和狨猴冲突试验)中的作用。在大鼠盖勒-西弗特试验中,于预试验前1小时口服给予5至40毫克/千克剂量的SB 200646A,所有剂量均使抑制性反应增加。仅在口服10毫克/千克时,非抑制性反应略有增加。在预试验前1小时口服给予1、2.5和5毫克/千克剂量的苯二氮䓬类抗焦虑药氯氮䓬,也使抑制性反应增加。仅在口服5毫克/千克时,氯氮䓬使非抑制性反应适度增加。在狨猴冲突试验中,训练狨猴按压杠杆以获取美味食物奖励。随后通过吹气抑制杠杆按压。在此过程中,口服2和5毫克/千克剂量的苯二氮䓬类抗焦虑药地西泮以及口服10和20毫克/千克剂量的SB 200646A均使抑制性反应增加。两种处理分别在口服2和20毫克/千克时使非抑制性反应略有增加。结合SB 200646A先前在大鼠社交互动试验中的作用,这有力地证明5-HT2C/2B受体拮抗剂可能具有抗焦虑特性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验